Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vaginal Estrogen vs Vaginal Estrogen + Hyaluronic Acid for GSM
NCT07038070Withdrawn
- Sponsor
- NYU Langone Health
- Start
- Jul 2025
- Primary completion
- May 2026
- Modality
- Polymer-based Nanoparticles, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised trial of hyaluronic acid in genitourinary syndrome of menopause (GSM) (2 arms), sponsored by NYU Langone Health. Primary endpoint: Vulvovaginal Symptom Questionnaire Score at 16 weeks. Planned start Jul 2025; status: withdrawn.
02
Drugs
hyaluronic acid
03
Conditions
genitourinary syndrome of menopause (GSM)
Beyond the preview
Go deeper on NCT07038070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07038070.